Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Phase 3 Completed 133 enrolled Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will analyse the dose-dependent effect of olmesartan medoxomil on the change in arterial stiffness in subjects with hypertension and metabolic syndrome

Timeline

Start: 2008-08
Primary completion: 2011-05
Completion: 2011-05

Publications

Laurent S, Boutouyrie P; Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014 Oct;64(4):709-16. doi: 10.1161/HYPERTENSIONAHA.114.03282. Epub 2014 Jul 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olmesartan medoxomil	Unknown	20 mg	Oral
Subject	Olmesartan medoxomil	Unknown	40 mg	Oral
Subject	Olmesartan medoxomil	Unknown	80 mg	Oral

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Summary

Timeline

Publications

Drugs

Indications